AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy
Department of Clinical Medicine, Division of Gastroenterology, Polo Pontino, Sapienza University of Rome, Rome, Italy. Digestive and Liver Disease
(Impact Factor: 2.96).
12/2009; 42(7):490-5. DOI: 10.1016/j.dld.2009.10.009
Very little data exist on the epidemiology of cholangiocarcinoma in Italy.
We focus on the descriptive epidemiology of cholangiocarcinoma in Italy.
Data on incidence were obtained from the Italian Association of Tumour Registries while mortality data were obtained from the Italian National Institute of Statistics.
A progressive increase of incidence with age was seen for extra-hepatic, intra-hepatic and not otherwise specified cholangiocarcinoma. Crude incidence rates were higher for extra-hepatic cholangiocarcinoma than those for intra-hepatic cholangiocarcinoma and in men compared to women. An increasing incidence trend was observed, from 1988 to 2005, for both extra-hepatic- and intra-hepatic cholangiocarcinoma with a 3-6% yearly increase and with a rate of increase higher for men than for women and for intra-hepatic- than for extra-hepatic cholangiocarcinoma. For intra-hepatic cholangiocarcinoma, the mortality rates progressively increased from 0.15 per million in 1980 to 5.9 per million in 2003, when mortality for this cancer surpassed extra-hepatic cholangiocarcinoma. Mortality rates for extra-hepatic cholangiocarcinoma showed an increasing trend from 1980 to 1994 but, in contrast to intra-hepatic cholangiocarcinoma, a stable or slightly decreasing trend from 1995 to 2003 was observed.
In Italy, cholangiocarcinoma showed a progressive increase in incidence and mortality in the last two decades mainly in intra-hepatic cholangiocarcinoma.
Available from: Timothy M Pawlik
- "More recent studies from Italy and Germany also reported rises in iCCA. In Italy iCCA mortality rates increased from 0.2 to 5.9 per million between 1980 and 2003  and in Germany iCCA mortality more than tripled between 1998 and 2008 . Incidence rates of iCCA have also recently increased in Korea, with an annual percent change (APC) of 8% in males and 11% in females, between 1999 and 2005 . "
Journal of Hepatology 06/2014; 60(6). DOI:10.1016/j.jhep.2014.01.021 · 11.34 Impact Factor
Available from: Giovanni Brandi
- "The current ICC incidence has now reached or even overtaken that of ECC which instead has remained stable or slightly decreased [2–4]. This trend has also been observed in Italy where ICC mortality considerably increased (from 0.01 to 0.59/100,000) from 1980 to 2003, overtaking the incidence of ECC . "
[Show abstract] [Hide abstract]
We conducted a case–control analysis to explore the association between occupational exposure to asbestos and cholangiocarcinoma (CC).
The study was based on historical data from 155 consecutive patients with CC [69 intrahepatic CC (ICC) and 86 extrahepatic CC (ECC)] referred to Sant’Orsola-Malpighi University Hospital between 2006 and 2010. The cases were individually matched by calendar period of birth, sex, and region of residence to historical hospital and population controls. Occupational exposure to asbestos was retrospectively assessed considering job titles obtained from work histories. Separate conditional logistic regression models were applied for ECC and ICC. Estimates were adjusted for smoking status and socioeconomic class.
We matched 149 controls (median birth year: 1947; males: 56 %) to 41 cases of ICC (median birth year: 1946; males: 56 %) and 212 controls (median birth year: 1945; males: 48 %) to 59 cases of ECC (median birth year: 1945; males 51 %); 53 cases were not matched due to residence or birth year. We found an increased risk of ICC in workers exposed to asbestos (adjusted OR 4.81, 95 % CI 1.73–13.33); we also observed suggestive evidence that asbestos exposure might be associated with ECC (adjusted OR 2.09, 95 % CI 0.83–5.27). Sensitivity analysis restricted to patients from the Province of Bologna produced confirmatory figures.
Our findings suggest that ICC could be associated with asbestos exposure; a chronic inflammatory pathway is hypothesized. Exposure to asbestos could be one of the determinants of the progressive rise in the incidence of ICC during the last 30 years.
Cancer Causes and Control 02/2013; 24(5). DOI:10.1007/s10552-013-0167-3 · 2.74 Impact Factor
Available from: PubMed Central
- "Epidemiological data show that intrahepatic cholangiocarcinoma is increasing in incidence, prevalence, and mortality worldwide [2, 3]. In particular, in the past three decades, a progressive increase of mortality for intrahepatic CC has been reported, while mortality for extrahepatic CC is stable or slightly decreasing . "
[Show abstract] [Hide abstract]
ABSTRACT: Epidemiological data from the last years show an increasing trend of incidence and mortality of cholangiocarcinoma (CC) worldwide. Many pathophysiologic aspects of this neoplasia are still unknown and need to be fully discovered. However, several progresses were recently made in order to establish the molecular mechanisms involved in the transformation and growth of malignant cholangiocytes. The principal concept that at least seems to be established is that cholangiocarcinogenesis is a multistep cellular process evolving from a normal condition of the epithelial biliary cells through a chronic inflammation status ending with malignant transformation. The bad prognosis related to CC justifies why a better identification of the molecular mechanisms involved in the growth and progression of this cancer is required for the development of effective preventive measures and valid treatment regimens. This Paper describes the scientific progresses made in the last years in defining the molecular pathways implicated in the generation of this devastating disease.
01/2012; 2012(10):630543. DOI:10.1155/2012/630543
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.